CCR2 and neoplasm: Whereas previous studies have shown that targeting suppressive monocytes in PDAC with a CCR2 inhibitor could enhance chemotherapy [31,42], in our current study, inhibition of monocytes from entering the tumor with a CCR2 inhibitor did not significantly affect the chemo/anti-LIF/anti-PD-L1 response.